Savara MOLBREEVI MAA Accepted by UK MHRA for PAP
Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...
BOSTON, March 30, 2026 Praxis Precision Medicines has achieved a major regulatory milestone as the U.S. Food and Drug...
CARLSBAD, California, March 23, 2026 Ionis Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted...
Rare Disease Biologic Advances Toward U.S. Approval – February 19, 2026 | Tarrytown, New York Regeneron Pharmaceuticals announced that...
Tokyo & Cambridge, Massachusetts, January 25, 2026 — Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food...
